Tyr240
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr240  -  SHC1 iso2 (human)

Site Information
EPPDHQyyNDFPGKE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448510
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 32 ) , [32P] bio-synthetic labeling ( 32 ) , mass spectrometry ( 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ) , mutation of modification site ( 2 , 28 , 29 , 30 , 31 ) , phospho-antibody ( 1 , 3 , 4 , 31 ) , phosphopeptide mapping ( 32 ) , western blotting ( 1 , 3 )
Disease tissue studied:
breast cancer ( 1 , 13 ) , breast adenocarcinoma ( 13 ) , colorectal cancer ( 9 ) , colorectal carcinoma ( 9 ) , leukemia ( 5 , 22 , 23 , 24 , 25 , 26 , 27 , 31 ) , acute myelogenous leukemia ( 5 ) , chronic myelogenous leukemia ( 22 , 23 , 24 , 25 , 26 , 27 ) , T cell leukemia ( 31 ) , lung cancer ( 10 ) , non-small cell lung cancer ( 10 ) , lymphoma ( 11 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ) , anaplastic large cell lymphoma ( 11 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ) , pancreatic cancer ( 6 , 7 , 8 ) , thyroid cancer ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
PTPRJ (human) ( 3 ) , Ret (human) ( 3 )
Putative in vivo kinases:
EGFR (human) ( 32 ) , Lck (human) ( 2 ) , Syk (human) ( 31 ) , ZAP70 (human) ( 31 )
Kinases, in vitro:
EGFR (human) ( 32 ) , Syk (human) ( 31 ) , ZAP70 (human) ( 31 )
Treatments:
AG1478 ( 1 , 29 ) , AG490 ( 2 ) , CXCL12 ( 2 ) , EGF ( 1 , 32 ) , erlotinib ( 4 ) , IGF-1 ( 4 ) , insulin ( 30 ) , LPA ( 4 ) , PP1 ( 29 ) , PP2 ( 2 ) , PTX ( 2 ) , siRNA ( 2 ) , thrombin ( 29 )

Downstream Regulation
Effects of modification on SHC1 iso2:
activity, induced ( 29 ) , activity, inhibited ( 32 ) , molecular association, regulation ( 2 , 28 , 30 ) , phosphorylation ( 28 )
Effects of modification on biological processes:
cell growth, induced ( 32 ) , cell motility, altered ( 2 ) , cytoskeletal reorganization ( 2 ) , transcription, induced ( 32 )
Induce interaction with:
GRB2 (human) ( 2 , 30 ) , GRB2 (mouse) ( 28 ) , SHIP (mouse) ( 28 ) , VAV1 (human) ( 2 ) , ZAP70 (human) ( 2 )
Inhibit interaction with:
GRB2 (human) ( 32 )

References 

1

Deb TB, et al. (2014) PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression. Cell Cycle 13, 961-73
24552815   Curated Info

2

Patrussi L, et al. (2007) p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells. Blood 110, 1730-8
17537990   Curated Info

3

Iervolino A, et al. (2006) The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Res 66, 6280-7
16778204   Curated Info

4

Thelemann A, et al. (2005) Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 4, 356-76
15657067   Curated Info

5

Goss V (2004) CST Curation Set: 429; Year: 2004; Biosample/Treatment: cell line, HT-93/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Guo A (2004) CST Curation Set: 412; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/EGF &'||' Iressa/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Guo A (2004) CST Curation Set: 392; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/none/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Guo A (2004) CST Curation Set: 393; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/EGF/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/Iressa/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Li Y (2004) CST Curation Set: 369; Year: 2004; Biosample/Treatment: cell line, HT-29/Serum starved &'||' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Rikova K (2004) CST Curation Set: 355; Year: 2004; Biosample/Treatment: cell line, NCI-H1373/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Moritz A (2003) CST Curation Set: 224; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Moritz A (2003) CST Curation Set: 225; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Moritz A (2003) CST Curation Set: 195; Year: 2003; Biosample/Treatment: cell line, MDA-MB468/EGF; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Moritz A (2003) CST Curation Set: 178; Year: 2003; Biosample/Treatment: cell line, Karpas-299/-; Disease: T cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Moritz A (2003) CST Curation Set: 179; Year: 2003; Biosample/Treatment: cell line, Karpas-299/-; Disease: T cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Moritz A (2003) CST Curation Set: 180; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Moritz A (2003) CST Curation Set: 181; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

18

Moritz A (2003) CST Curation Set: 182; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

19

Moritz A (2003) CST Curation Set: 175; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

20

Moritz A (2003) CST Curation Set: 174; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

21

Moritz A (2003) CST Curation Set: 99; Year: 2003; Biosample/Treatment: cell line, Karpas-299/-; Disease: T cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

22

Moritz A (2003) CST Curation Set: 79; Year: 2003; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Moritz A (2003) CST Curation Set: 85; Year: 2003; Biosample/Treatment: cell line, K562/pervanadate; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

24

Moritz A (2003) CST Curation Set: 44; Year: 2003; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

25

Moritz A (2003) CST Curation Set: 46; Year: 2003; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

26

Moritz A (2003) CST Curation Set: 47; Year: 2003; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

27

Moritz A (2003) CST Curation Set: 31; Year: 2003; Biosample/Treatment: cell line, K562/pervanadate; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

28

Velazquez L, et al. (2000) The shc adaptor protein forms interdependent phosphotyrosine-mediated protein complexes in mast cells stimulated with interleukin 3. Blood 96, 132-8
10891441   Curated Info

29

Ricketts WA, Brown JH, Olefsky JM (1999) Pertussis toxin-sensitive and -insensitive thrombin stimulation of Shc phosphorylation and mitogenesis are mediated through distinct pathways. Mol Endocrinol 13, 1988-2001
10598576   Curated Info

30

Ishihara H, et al. (1998) Relative involvement of Shc tyrosine 239/240 and tyrosine 317 on insulin induced mitogenic signaling in rat1 fibroblasts expressing insulin receptors. Biochem Biophys Res Commun 252, 139-44
9813159   Curated Info

31

Walk SF, March ME, Ravichandran KS (1998) Roles of Lck, Syk and ZAP-70 tyrosine kinases in TCR-mediated phosphorylation of the adapter protein Shc. Eur J Immunol 28, 2265-75
9710204   Curated Info

32

Gotoh N, Toyoda M, Shibuya M (1997) Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation. Mol Cell Biol 17, 1824-31
9121430   Curated Info